Semaglutide is the active ingredient in Ozempic®, which is approved by the Food and Drug Administration (FDA) to help people with type 2 diabetes manage their blood sugar levels. Healthcare providers ...

This article was reviewed by Craig Primack, MD, FACP, FAAP, FOMA. Semaglutide — the active ingredient in the brand-name meds Ozempic, Wegovy, and Rybelsus — treats type 2 diabetes and obesity or ...

Cagrilintide and semaglutide have each been shown to induce weight loss as monotherapies. Data are needed on the coadministration of cagrilintide and semaglutide (called CagriSema) for weight ...

Semaglutide at a dose of 2.4 mg has established weight-loss and cardiovascular benefits, and cagrilintide at a dose of 2.4 mg has shown promising results in early-phase trials; the efficacy of the ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Oral semaglutide reduced risk for cardiovascular events ...

A groundbreaking international trial has found that semaglutide, a drug best known for treating diabetes and obesity, can also reverse a dangerous liver disease called MASH in nearly two-thirds of ...

Please provide your email address to receive an email when new articles are posted on . You've successfully added to your alerts. You will receive an email when new content is published. Click Here to ...

Semaglutide or tirzepatide should be the first line treatment for people living with obesity and most of its complications, according to a new framework for the pharmacological treatment of obesity ...

Mass General Brigham researchers found that total weight loss did not increase for patients who took semaglutide before having weight loss surgery, suggesting that a surgery first strategy could lead ...